• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Delcath Systems Inc.

Delcath Systems ticks up despite missed Q1 projections

May 11, 2021 By Sean Whooley

Delcath Systems (OTC:DCTH) shares ticked up slightly despite first-quarter results that missed the consensus forecast. The New York-based company posted losses of -$6.7 million, or -$1.04 per share, on sales of $388,000 for the three months ended March 31, 2021, for a -33% bottom-line slide on sales growth of 32%. Delcath’s EPS of -$1.04 came […]

Filed Under: Business/Financial News, MassDevice Earnings Roundup, Oncology, Wall Street Beat Tagged With: Delcath Systems Inc.

Delcath completes $22.2M offering

December 14, 2020 By Sean Whooley

Delcath Systems (OTC:DCTH) announced that it completed an underwritten public offering of common stock worth approximately $22.2 million. New York-based Delcath’s offering includes nearly 1.7 million shares of its common stock at a public offering price of $13.25 per share, bringing the gross proceeds before deductions to approximately $22.2 million, according to a news release. The […]

Filed Under: Business/Financial News, Funding Roundup, Oncology Tagged With: Delcath Systems Inc.

Delcath Systems names operations VP

December 10, 2020 By Danielle Kirsh

Delcath Systems recently announced that it appointed Kevin Muir as VP of commercial operations. Prior to joining the company, Muir was the director of sales for the embolic interventional oncology business at BTG, which was recently acquired by Boston Scientific. “We are thrilled that Kevin is joining the Delcath team as VP of commercial operations. […]

Filed Under: Business/Financial News Tagged With: Delcath Systems Inc.

Delcath names new CEO

October 2, 2020 By Sean Whooley

Delcath Systems (OTC:DCTH) announced that it appointed Gerard Michel as its new CEO, effective yesterday, Oct. 1, 2020. Michel assumed the role yesterday and also was appointed as a Class I director on the company’s board of directors, with that role continuing until the expiry of his term at the company’s 2022 annual meeting of stockholders, […]

Filed Under: Business/Financial News, Drug-Device Combinations, Oncology Tagged With: Delcath Systems Inc., Personnel Moves

Delcath Systems announces reverse stock split

December 24, 2019 By Chris Newmarker

A reverse stock split went into effect today for Delcath Systems (OTC:DCTH) — developer of the Chemostat hepatic delivery system for treating cancer. The 1-for-700 reverse stock split is meant to reduce the number of common stock shares and shares reserved for issuance to 1.2 million, from a previous 1.4 billion. The authorized number of shares […]

Filed Under: Business/Financial News, Drug-Device Combinations, News Well, Oncology Tagged With: Delcath Systems Inc.

Delcath Systems raises another $9.5m

August 20, 2019 By Nancy Crotti

Delcath Systems (OTC:DCTH) has closed on a $9.5 million private placement round, bringing the total amount raised since July to $29.5 million. The Queensbury, N.Y.-based company priced the round at $1,000 per unit, with each unit consisting of a preferred convertible share worth 16,667 common shares, at a 6¢ strike price, and a five-year warrant for […]

Filed Under: Business/Financial News, Funding Roundup, Oncology, Wall Street Beat Tagged With: BTG, Delcath Systems Inc.

Delcath Systems closes $20m private placement

July 23, 2019 By Danielle Kirsh

Delcath Systems (OTC:DCTH) last week said that it closed a $20 million private placement round for the liver cancer treatment it developed. The Queensbury, N.Y.-based company priced the round at $1,000 per unit, with each unit consisting of a preferred convertible share worth 16,667 common shares, at a 6¢ strike price, and a five-year warrant another […]

Filed Under: Oncology Tagged With: Delcath Systems Inc.

Delcath wins approval for Chemosat in Brazil

February 11, 2019 By Sarah Faulkner

Delcath Systems (OTC:DCTH) said today that it won medical device approval for its Chemosat hepatic delivery system from the national health authority in Brazil. The New York-based company plans to market and sell Chemosat in Brazil for the percutaneous intra-arterial administration of melphalan hydrochloride to the liver with subsequent extracorporeal filtration of blood. Get the full story […]

Filed Under: Drug-Device Combinations, Oncology, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Delcath Systems Inc.

Delcath inks European licensing deal for Chemosat

December 26, 2018 By Sarah Faulkner

Delcath Systems (OTC:DCTH) said this week that it inked a licensing deal with Germany-based medac for the commercialization of Chemosat in Europe. According to the terms of the seven-year agreement, Delcath’s European subsidiary will exclusively license its Chemosat system to Medac for sale in the EU, Norway, Liechtenstein, Switzerland and the UK. Medac is slated to […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Oncology, Wall Street Beat Tagged With: Delcath Systems Inc.

Delcath registers $100m offering

October 26, 2018 By Sarah Faulkner

Delcath Systems (NSDQ:DCTH) registered a $100 million offering with the SEC this week to support the development of its system designed to administer high-dose chemotherapy to the liver. The company’s product, melphalan hydrochloride for injection for use with the Delcath hepatic delivery system, won CE Mark clearance in Europe in 2012 and is under consideration by the FDA […]

Filed Under: Drug-Device Combinations, Funding Roundup, Oncology, Pharmaceutical, Wall Street Beat Tagged With: Delcath Systems Inc.

DelCath closes $8m rights offering

September 28, 2018 By Fink Densford

Delcath Systems (NSDQ:DCTH) said yesterday it closed a previously announced rights offering bringing in approximately $8.1 million. The New York-based company said that it received approximately 4.3 million basic subscriptions and 418,207 oversubscriptions for a total of approximately 4.7 million subscriptions. Read the whole story on our sister site, Drug Delivery Business News

Filed Under: Business/Financial News, Wall Street Beat Tagged With: Delcath Systems Inc.

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 9
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS